118
Cordlife Group Limited
Annual Report 2016
for the financial year ended 30 June 2016
Notes to
The Financial Statements
40. Segment reporting (cont’d)
Segment results
Banking
$’000
Diagnostics
$’000
Others*
$’000
Total
$’000
Year ended 30 June 2016
Depreciation and amortisation
(2,476)
(39)
–
(2,515)
Share of results of associate
(76)
–
–
(76)
Segment profit/(loss)
1,645
(58)
–
1,587
Fair value gain on investment properties
(220)
Fair value changes on financial asset
designated at fair value through profit or loss
4,548
Fair value changes on derivative asset
2,519
Exchange differences
6,014
Gain on sale of financial asset designated
at fair value through profit or loss
151
Gain on sale of convertible note
5,012
Remeasurement loss on previously held
equity interest in subsidiary
(1,594)
Other expenses
(2,409)
Finance income
5,346
Finance costs
(5,589)
Note repurchase expense
(2,025)
Profit before income tax
13,340
Income tax
(760)
Profit for the year
12,580
Year ended 30 June 2015
Depreciation and amortisation
(1,653)
(35)
–
(1,688)
Share of results of associate
(436)
–
–
(436)
Segment profit/(loss)
5,699
(248)
(2)
5,449
Impairment loss on investment in associate
(2,646)
Fair value gain on investment properties
265
Fair value changes on financial asset
designated at fair value through profit or loss
10,364
Fair value changes on derivative asset
12,922
Exchange differences
4,653
Finance income
7,043
Finance costs
(4,782)
Profit before income tax
33,268
Income tax
(1,143)
Profit for the year
32,125
*
Others refer to results of subsidiaries not in the principal activities of the provision of cord blood and cord lining
banking and diagnostics services.
